Generation of human iPSCs from fetal prostate fibroblasts HPrF

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F19%3A00072539" target="_blank" >RIV/00159816:_____/19:00072539 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.scr.2019.101405" target="_blank" >http://dx.doi.org/10.1016/j.scr.2019.101405</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.scr.2019.101405" target="_blank" >10.1016/j.scr.2019.101405</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Generation of human iPSCs from fetal prostate fibroblasts HPrF

Popis výsledku v původním jazyce

Human induced pluripotent stem cell line was generated from commercially available primary human prostate fibroblasts HPrF derived from a fetus, aged 18-24 weeks of gestation. The fibroblast cell line was reprogrammed with Yamanaka factors (OCT4, SOX2, c-MYC, KLF4) using CytoTune (TM)-iPS 2.0 Sendai Reprogramming Kit. Pluripotency of the derived transgene-free iPS cell line was confirmed both in vitro by detecting the expression of factors of pluripotency on a single-cell level, and in vivo using teratoma formation assay. This iPS cell line will be a useful tool for studying both normal prostate development and prostate cancer disease.

Název v anglickém jazyce

Generation of human iPSCs from fetal prostate fibroblasts HPrF

Popis výsledku anglicky

Human induced pluripotent stem cell line was generated from commercially available primary human prostate fibroblasts HPrF derived from a fetus, aged 18-24 weeks of gestation. The fibroblast cell line was reprogrammed with Yamanaka factors (OCT4, SOX2, c-MYC, KLF4) using CytoTune (TM)-iPS 2.0 Sendai Reprogramming Kit. Pluripotency of the derived transgene-free iPS cell line was confirmed both in vitro by detecting the expression of factors of pluripotency on a single-cell level, and in vivo using teratoma formation assay. This iPS cell line will be a useful tool for studying both normal prostate development and prostate cancer disease.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

20602 - Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])

Projekt

<a href="/cs/project/LQ1605" target="_blank" >LQ1605: Translační medicína</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů